Erythrocytes as Carriers for Recombinant Cloned DNA
The concept of carriers in pharmacology has evolved because various problems complicate the objective of delivering pharmacologically-active substances to the appropriate target in appropriate amounts. One objective achieved by carriers is protection. Small molecular weight drugs for example can be protected from serum enzymes and binding proteins by a carrier. Enzymes and proteins can be protected from circulating antibodies and it is possible that they can be sequestered from the immune system so that an immune response is not initiated. A second objective is carrier-mediated delivery to specific target sites. For example several groups (Alving et al., 1978; Black et al., 1977; New et al., 1978) have shown that liposomes containing antimonial drugs are more effective than the free drug for the treatment of leishmaniasis, presumably because liposomes are specifically taken up by the same reticuloendothelial cells that are infected by the intracellular parasite.
KeywordsRecipient Cell Bacteriophage Lambda Magnetic Microsphere Free Phage Cloning Vehicle
Unable to display preview. Download preview PDF.
- Humphreys, J., Edlind, T., and Ihler, G., 1981, Entrapment of viral vectors for recombinant DNA in erythrocytes, J. Appl. Biochem., (in press).Google Scholar
- Ihler, G., 1979, Potential use of erythrocytes as carriers for enzymes and drugs, in: “Drug Carriers in Biology and Medicine”, Gregoriadis, G., ed., Academic Press, London.Google Scholar
- Mackay, D. J., and Bode, V. C., 1976, Binding to isolated phage receptors and.ADNA release in vitro, 72: 167.Google Scholar